Celdara Medical, LLC announced receipt of a clinical milestone payment from partner Celyad, SA (NASDAQ: CYAD). This milestone payment is related to the advancement of the OnCyte product candidate CM-CS1, currently in Phase I clinical development (NCT02203825) at the Dana Farber Cancer Institute. OnCyte was acquired by Celyad from Celdara […]
Today Celdara Medical, Virtici, and MBV announced their formation of the first collaborative nationwide network for the development of early stage biotechnologies. The goals are simple: to improve human health by identifying the highest potential innovations in medicine, and developing them into the clinic. The companies share a highly collaborative […]
Celdara Medical, LLC and Pulmatrix, Inc. (NASDAQ: PULM) today announced that the National Heart Lung and Blood Institute of the National Institutes of Health has awarded a three-year, $1.7 million Fast Track Small Business Innovation Research grant to fund the companies’ development of an inhaled biologic to treat idiopathic pulmonary […]
Celdara Medical, LLC announced today that it has elected Lita Nelsen to its Board of Directors, and appointed her as a Member of the Company. “Lita is trailblazer and an innovator, and sets the bar for what the interface between academia and industry can be,” said Jake Reder, Ph.D., cofounder […]
Celdara Medical, LLC announced today that it has received a $288k SBIR Phase I award from the National Institutes of Health’s National Cancer Institute (NCI). This award will support proof-of-concept for combination immunotherapies for the treatment of melanoma. “Immunotherapies have clearly demonstrated their worth in the clinic, but none is […]
Celdara Medical, LLC announced today that it has received national recognition from the Small Business Administration (SBA) in the form of a Tibbetts Award. The award recognizes unique contributions to the Small Business Innovation Research (SBIR) Program. John Williams, the Director of Innovation and Technology in the Office of Investment […]
Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announced the acquisition of OnCyte, LLC a division of Celdara Medical, and its portfolio of immuno-oncology CAR T cell product candidates. The acquisition marks Cardio3 Biosciences’ entry into the rapidly growing […]
Celdara Medical, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of CM-CS1 in patients with Acute Myeloid Leukemia (AML)/Advanced Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM). Celdara Medical plans to initiate a […]
Today Celdara Medical, LLC announced the opening of their first site in New York City. “New York is a hub of biomedical innovation, especially in the city’s many storied academic and clinical research centers. Our expansion allows us to fully participate in this vibrant ecosystem. We believe our model – […]
Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas. Virtici and Celdara Medical are affiliated, independent companies that build and develop […]